Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer

被引：3

作者：

Ota, Takayo ^{[1
]}

Miyatake, Nozomi ^{[1
]}

Tanaka, Noriko ^{[2
]}

Hasegawa, Yoshikazu ^{[1
]}

Tokunaga, Masahiro ^{[2
]}

Tsukuda, Hiroshi ^{[1
]}

Fukuoka, Masahiro ^{[1
]}

机构：

[1] Izumi Municipal Hosp, Dept Med Oncol, 4-10-10 Fuchu, Izumi, Osaka 5940071, Japan

[2] Izumi Municipal Hosp, Dept Radiol, Izumi, Osaka, Japan

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 2018年 / 34卷 / 04期

关键词：

Breast cancer; disseminated carcinomatosis of the bone marrow; hormone therapy; zoledronic acid; GASTRIC-CANCER; METASTASIS; PROGNOSIS;

D O I：

10.1080/09513590.2017.1393063

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Disseminated carcinomatosis of the bone marrow (DCBM) is diffusely invasive bone metastasis resulting from solid tumors. DCBM is often associated with disseminated intravascular coagulation (DIC) or hemolytic anemia. Generally, DCBM treatment includes cytotoxic chemotherapy for underlying solid tumors and management of hematological conditions if present. We report a case of DCBM accompanied with DIC in hormone receptor-positive breast cancer. Due to her life-threatening condition, we used hormone therapies, not cytotoxic chemotherapies, to treat her DCBM. With zoledronic acid, her DIC and general condition gradually improved and eventually she could return to her daily life. If DCBM occurs in hormone receptor-positive breast cancer, hormone therapy can be one of the treatment choices.

引用

页码：286 / 289

页数：4

共 50 条

[21] Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy
Montemurro, Filippo
Aglietta, Massimo
ENDOCRINE-RELATED CANCER, 2009, 16 (04) : 1091 - 1102
[22] Chemotherapy use for hormone receptor-positive, node-negative breast cancer
Hassett, M. J.
Hughes, M. E.
Niland, J. C.
Edge, S. B.
Theriault, R. L.
Wong, Y.
Wilson, J.
Carter, B. W.
Blayney, D. W.
Weeks, J. C.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[23] Weakly hormone receptor-positive breast cancer and use of adjuvant hormonal therapy
Lin, Cassandra M.
Jaswal, Jasbir
Vandenberg, Theodore
Tuck, Alan
Brackstone, Muriel
CURRENT ONCOLOGY, 2013, 20 (06) : E612 - E613
[24] Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer
Tan, Sing-Huang
Wolff, Antonio C.
CLINICAL BREAST CANCER, 2007, 7 (06) : 455 - 464
[25] Metformin Is Associated with More Hormone Receptor-positive Breast Cancers
Bowden, Sylvie
Yin, Lu
Schellenberg, Angela
Hong, Nicole Look
Chen, Shiyi
Fulton, Courtney
Ihibhunu, Happy
Mikail, Moiz
Matei, Andreea
Leong, Wey
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S559 - S560
[26] Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
Lin, Mingxi
Jin, Yizi
Yang, Ziyi
Hu, Xichun
Zhang, Jian
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
[27] An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer
Verma, S.
Sehdev, S.
Joy, A.
Madarnas, Y.
Younus, J.
Roy, J. A.
CURRENT ONCOLOGY, 2009, 16 : S3 - S15
[28] Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Ohno, Shinji
CLINICAL BREAST CANCER, 2016, 16 (04) : 238 - 246
[29] DETERMINATION AND CLINICAL SIGNIFICANCE OF BONE PSEUDOPROGRESSION IN HORMONE RECEPTOR-POSITIVE METASTATIC BREAST CANCER
Zhang, Jian
Lin, Mingxi
BREAST, 2021, 59 : S52 - S53
[30] Weight Gain after Hormone Receptor-Positive Breast Cancer
Goyal, Archita
Milner, Gabrielle E.
Cimino-Mathews, Ashley
Visvanathan, Kala
Wolff, Antonio C.
Sharma, Dipali
Sheng, Jennifer Y.
CURRENT ONCOLOGY, 2022, 29 (06) : 4090 - 4103

← 1 2 3 4 5 →